Objective To determine the prevalence of invasive bacterial infection (IBI) in a UK cohort of febrile infants aged 90 days and younger with positive urinalysis (PU) results. Design A planned secondary analysis of data from the Febrile Infant Diagnostic Assessment and Outcome study, a prospective multicentre observational cohort study. Setting 35 paediatric emergency departments and assessment units across the UK and Ireland, between 6 July 2022 and 31 August 2023. Patients Febrile infants aged 90 days and younger presenting to emergency care. Main outcome measures IBI rates, namely bacterial meningitis or bacteraemia, among febrile infants with PU results were compared with those with negative urinalysis (NU) results. Results 1480 of 1821 infants underwent urinalysis testing. 549 infants had PU results and 931 had NU results. 42/549 (7.7%) and 20/931 (2.2%) infants had IBI in the PU and NU groups, respectively. Of the IBI cases within the PU group, 5/549 (0.9%) were bacterial meningitis and 39/549 (7.1%) were bacteraemia, with two concomitant cases. Of the IBI cases in the NU group, there were 4/931 (0.4%) cases of bacterial meningitis and 18/931 (1.9%) cases of bacteraemia, with two concomitant cases. There were no bacterial meningitis cases in infants over 60 days of age or those with confirmed urinary tract infection (UTI). Conclusions The prevalence of bacteraemia was high (7.1%) among PU infants, while the prevalence of bacterial meningitis was low (0.9%), with PU or NU. These findings support existing data that older infants with suspected UTI are at low risk of bacterial meningitis.
Background: Accurately distinguishing bacterial from non-bacterial infections is essential to guide antibiotic use but remains clinically challenging. Current biomarkers such as C-reactive protein and procalcitonin have limited diagnostic accuracy. Objective: To identify novel blood protein biomarkers with clinically acceptable performance for differentiating bacterial from non-bacterial infections. Methods: Following PRISMA guidelines, we systematically searched Medline and prior reviews (2010–2024) for studies evaluating the diagnostic accuracy of protein biomarkers in serum or plasma for bacterial infection. Biomarkers were considered clinically useful if sensitivity ≥90%, specificity ≥80%, or AUC ≥0.9, was reported in studies with low risk of bias (assessed via modified QUADAS-2). Results: From 2,236 records, 47 studies were included, assessing 50 individual biomarkers and 12 signatures. Two individual biomarkers (LCN2, IFN-α) and three multi-marker signatures (TRAIL+IP-10+CRP, E-selectin+IL-18+NCAM1+LCN2+IFN-γ, and E-selectin+IL-18+NCAM1+LG3BP+LCN2+IFN-γ) met pre-defined performance thresholds. TRAIL+IP-10+CRP showed consistent performance across six studies. Conclusions: TRAIL+IP-10+CRP and LCN2 are promising host-response biomarkers for bacterial infection. Multi-marker panels may enhance diagnostic accuracy but require further validation. These tools have the potential to improve clinical decision-making and reduce unnecessary antibiotic use.
Objective: The objective of this scoping review is to understand the extent and type of evidence in relation to bacterial diagnostic approaches in paediatric cancer patients with febrile neutropenia (FN), with the goals of highlighting the best practice approach to conventional microbiological testing used in current clinical practice and explore the role of emerging technologies as potential diagnostic tools. Introduction: FN is a common complication for children undergoing chemotherapy for cancer, with bacterial bloodstream infection responsible for the majority of serious adverse events. Current diagnostic approaches have limited sensitivity and long turnaround times. Improved diagnostics are required to strengthen clinical decision rules and support the safer use of reduced-intensity management pathways. Eligibility Criteria: Children up to their 18th birthday with a diagnosis of cancer will be included, looking at bacterial diagnostic methods used in the evaluation of FN. Studies conducted across all healthcare settings will be considered. Studies focusing exclusively on viral or fungal diagnostics will be excluded, as will those not involving human participants. Methods: The review will be conducted in accordance with Joanna Briggs Institute and PRISMA-Scoping Review methodology. A comprehensive search of MEDLINE, Embase, Web of Science Core Collection and grey literature will be conducted to identify published and unpublished studies from 2011 onwards, with no language restrictions. Primary research studies of any design will be included, however case reports with fewer than 10 participants will be excluded. Two independent reviewers will screen studies and extract data. Any discrepancies will be resolved by consensus, involving a third reviewer if necessary. Findings will be synthesised and presented using tables and figures, accompanied by a narrative synthesis to address the research question.
To identify and validate plasma host-response protein biomarkers that improve discrimination of bacterial infection in febrile infants ≤90 days of age, and to assess whether novel biomarkers add value beyond established markers. Sub-study of the prospective multicentre Febrile Infant Diagnostic Assessment and Outcome (FIDO) cohort. Novel biomarkers were identified through plasma proteomic profiling (Olink®) and combined with biomarkers and signatures from the literature for verification using Luminex and ELISA platforms. Diagnostic performance of novel biomarkers, established markers (CRP, PCT), and multi-protein signatures was evaluated. Proteomic profiling of 110 samples identified 174 proteins differentially expressed between bacterial and viral infections, revealing distinct pathogen-specific immune signatures. Verification in the full cohort (n = 445) demonstrated PCT had the highest individual accuracy for invasive bacterial infection (IBI) (AUC 0.89). Combining PCT with novel biomarkers, particularly lipocalin-2 (LCN2), improved discrimination (AUC 0.96). Diagnostic performance for the combined IBI/urinary tract infection (UTI) outcome was consistently lower (AUC <0.8). Febrile infants demonstrate biologically coherent host-response signatures that can be leveraged diagnostically. A PCT-LCN2 combination showed excellent accuracy for identifying IBI and may support future biomarker-guided diagnostic strategies, while reliable discrimination of UTI remains challenging.
Background: Distinguishing bacterial from viral or inflammatory conditions in hospitalised children is clinically challenging due to overlapping clinical features and limitations of existing diagnostics. Culture-based tests are slow, and commonly used biomarkers such as C-reactive protein (CRP) lack sufficient accuracy, contributing to empirical antibiotic use and antimicrobial resistance. We aimed to evaluate the diagnostic performance of novel blood protein biomarkers for bacterial infection in children admitted with infection or inflammatory illness. Methods: We performed a prospective observational diagnostic accuracy study of children ≤ 16 years admitted to the Royal Belfast Hospital for Sick Children (2020–2023) with bacterial infection, viral infection or inflammatory illness. Plasma samples were analysed for previously reported novel biomarkers and signatures (LCN2; TRAIL + IP-10 + CRP; E-selectin+IL18 + NCAM1+LCN2 + IFN-γ + LG3BP and E-selectin+IL18 + NCAM1+LCN2 + IFN-γ). The diagnostic accuracy of individual biomarkers and biomarker signatures was assessed using ROC curves. Results: Fifty-two children were included (13 bacterial, 20 viral, 19 inflammatory). All evaluated biomarker signatures and LCN2 distinguished bacterial from viral infection (AUC 0.819–0.935), with the TRAIL + IP-10 + CRP signature achieving the highest accuracy (AUC 0.935). In bacterial–inflammatory comparisons, performance was lower (AUCs 0.607–0.745); the E-selectin + IL-18 + NCAM1+LCN2 + IFN-γ signature performed best (AUC 0.745) and outperformed CRP (AUC 0.595). A novel three-protein signature (E-selectin+LCN2 + IFN-γ) had a significantly higher AUC than CRP for distinguishing bacterial infections from non-bacterial (viral and inflammatory combined). Conclusions: Several novel host protein biomarkers and signatures had a higher diagnostic accuracy than CRP for differentiating bacterial from non-bacterial illness (viral and inflammatory) in hospitalised children. These findings provide preliminary evidence for biomarker-guided diagnostics to improve accuracy and facilitate earlier antibiotic de-escalation. Importantly, the identification of the novel signature (E-selectin+LCN2 + IFN-γ) should be considered hypothesis-generating and requires external validation.
Objective: To summarise the evidence on the use of metagenomic next-generation sequencing to characterise the respiratory microbiome in paediatric patients with cystic fibrosis (CF), with a focus on early-life microbial evolution, development of the airway resistome and the clinical utility of sequencing-based approaches in practice. Introduction: Early-life development of the respiratory microbiome plays a significant role in shaping long-term pulmonary outcomes in children with CF. Conventional culture-based diagnostics lack the sensitivity required to capture the complexity of airway microbial communities. Metagenomic sequencing enables culture-independent identification of pathogens and antimicrobial resistance genes, resulting in an expansion of literature utilising sequencing-based approaches to characterise the CF respiratory microbiome. The clinical significance of early-life microbiome variation and the translational value of these data remain poorly understood. Eligibility Criteria: Inclusion- studies that utilise metagenomic sequencing, including targeted 16S rRNA amplicon sequencing and untargeted shotgun sequencing, to characterise the bacterial respiratory microbiome of children and young people up to their 18th birthday with CF. Exclusion- animal models; in vitro, tissue-based or in silico studies; case-studies <10 participants, editorials, conference abstracts and review studies. Methods: The review will be conducted in accordance with Joanna Briggs Institute and PRISMA-Scoping Review (ScR) methodology. The databases to be searched will include Medline, and Web of Science with an additional for grey literature search via Google and Google Scholar, with no time or language restrictions. Two independent reviewers will screen by title and abstract, then by full-text review. The results of the search, study selection process and reasons for exclusion at full-text review will be reported in the PRISMA-ScR flow diagram. Data will be extracted into a chart. Key study characteristics and findings will be presented and discussed descriptively, supported by tabular summaries; highlighting how the available evidence relates to the review question.